Space Ark Biomedical CO., LTD.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
The "Cell Ark Mission" aims to utilize gene-editing technology to store the metabolic pathway genes of various essential nutrients within cellular chromosomes. This provides humanity with a brand-new survival solution under extreme conditions such as climate change, species extinction, nuclear conflict, and food or medicine shortages, and is poised to become an innovative approach for sustainably obtaining nutrition in both space exploration and terrestrial environments. Space Ark Biomedical CO., LTD. utilizes the "Picasso PGASO" synthetic biology platform and cell-editing technology to treat probiotics and yeast cells as precisely designable micro-factories. Preliminary research has successfully prepared radiation-resistant stress-tolerance components that can be embedded into cell membranes to protect cells from free radical damage caused by cosmic rays. Initial data indicates that cells can maintain stability under adverse conditions such as ultraviolet light, radiation, and toxic substances. The concept product, Asta-Sense, won the Gold Medal in the Runspace 2025 Practical Category competition. It senses space radiation through the color changes (astaxanthin/phycocyanin) of genetically modified microorganisms, leveraging the high resilience of biodetection to mitigate the radiation risks to space missions when electronic sensors fail. In the future, Space Ark Biomedical CO., LTD. will further invite experts from various fields to jointly develop integrated space biological experiment equipment, aiming for applications on the International Space Station (ISS) or CubeSats for drug development and lab-on-chip research. This will integrate spectrometers, organ-on-a-chip biomimetic bioreactors, automated culture measurement, and bioinformatics, utilizing a stacked microfluidic design to run multiple sets of experiments simultaneously to increase efficiency and reduce costs. Space Ark Biomedical CO., LTD. expects to complete the prototype by 2027, which can be further extended to space manufacturing and human health research, opening up brand-new possibilities for humanity in the era of pursuing space exploration and sustainable resources.
The content above was translated by Ai
Founded Year
2017
Unified Business No.
52537587
Status
Active
Number of Employees
0
Total Paid-in
Capital
5,050,000 (NT$)
Location of Company
Taiwan
, Taipei City
Website
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Space Ark Biomedical CO., LTD. (parent company AllBio Biotech) is a space biotechnology company dedicated to solving astronaut health issues and the challenges of in-space biomanufacturing, making space colonization possible for humanity by 2040 through biotechnology! We aim to solve these two greatest challenges of space health and space manufacturing. At the same time, these biotechnologies can also solve various problems on Earth, such as an aging population (muscle atrophy), microplastic pollution, and carbon emissions, possessing broad market application potential. To this end, we will build a biotechnology platform (CosmoCare Ecosystem) that makes space travel and space colonization possible.
The content above was translated by Ai
